期刊
ACS INFECTIOUS DISEASES
卷 7, 期 6, 页码 1818-1832出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.1c00110
关键词
Plasmodium falciparum; proteasome; nonpeptidomimetic inhibitors; high throughput screening; malaria drug discovery
资金
- Tres Cantos Open Lab Foundation (TCOLF)
- GSK
- Australian National Health and Medical Research Council
Through screening compounds, this study identified four chemical families with selectivity for the P. falciparum proteasome, providing a good starting point for the development of new antimalarial drugs.
The Ubiquitin Proteasome System is the main proteolytic pathway in eukaryotic cells, playing a role in key cellular processes. The essentiality of the Plasmodium falciparum proteasome is well validated, underlying its potential as an antimalarial target, but selective compounds are required to avoid cytotoxic effects in humans. Almost 550000 compounds were tested for the inhibition of the chymotrypsin-like activity of the P. falciparum proteasome using a Proteasome-GLO luminescence assay. Hits were confirmed in an orthogonal enzyme assay using Rho110-labeled peptides, and selectivity was assessed against the human proteasome. Four nonpeptidomimetic chemical families with some selectivity for the P. falciparum proteasome were identified and characterized in assays of proteasome trypsin and caspase activities and in parasite growth inhibition assays. Target engagement studies were performed, validating our approach. Hits identified are good starting points for the development of new antimalarial drugs and as tools to better understand proteasome function in P. falciparum.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据